07:25 AM EST, 02/26/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) reported a Q4 net loss Wednesday of $2.71 per diluted share, narrowing from a loss of $5.68 a year earlier.

Analysts polled by FactSet expected EPS loss of $3.92.

Revenue for the quarter ended Dec. 31 was $103.3 million. Analysts surveyed by FactSet expected $99.1 million.

As of Dec. 31, the company said it had $931.3 million in cash and or cash equivalents on hand, compared with $634.1 million a year earlier.

The company shares were up almost 5% in recent premarket activity.